Sutro Biopharma Inc
NASDAQ:STRO
Sutro Biopharma Inc
Sutro Biopharma Inc. engages in the drug discovery, development and manufacture of pharmaceutical products. The company is headquartered in South San Francisco, California and currently employs 224 full-time employees. The company went IPO on 2018-09-27. The company is focused on deploying its integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF, to create a variety of protein therapeutics, initially for cancer. The company is engaged in designing therapeutics using potent modalities, including cytokine-based therapeutics, immuno-oncology agents, antibody-drug conjugates (ADCs) and bispecific antibodies that are directed against clinically validated targets. Its product candidate includes STRO-002 and STRO-001. STRO-002, is an ADC directed against folate receptor-alpha, for patients with FolRα-expressing cancers, such as ovarian and endometrial cancers. STRO-001, is an ADC directed against CD74, for patients with B-cell malignancies, such as multiple myeloma and non-Hodgkin lymphoma. Its product candidates are designed and optimized for therapeutic index by placing linker-warheads at specific locations within the antibody.
Sutro Biopharma Inc. engages in the drug discovery, development and manufacture of pharmaceutical products. The company is headquartered in South San Francisco, California and currently employs 224 full-time employees. The company went IPO on 2018-09-27. The company is focused on deploying its integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF, to create a variety of protein therapeutics, initially for cancer. The company is engaged in designing therapeutics using potent modalities, including cytokine-based therapeutics, immuno-oncology agents, antibody-drug conjugates (ADCs) and bispecific antibodies that are directed against clinically validated targets. Its product candidate includes STRO-002 and STRO-001. STRO-002, is an ADC directed against folate receptor-alpha, for patients with FolRα-expressing cancers, such as ovarian and endometrial cancers. STRO-001, is an ADC directed against CD74, for patients with B-cell malignancies, such as multiple myeloma and non-Hodgkin lymphoma. Its product candidates are designed and optimized for therapeutic index by placing linker-warheads at specific locations within the antibody.
Strategic Shift: Sutro is deprioritizing its investment in luvelta, focusing resources on three next-generation ADC preclinical programs, including STRO-004, STRO-006, and a dual-payload ADC.
Restructuring: The company will cut its workforce by nearly 50% and externalize cell-free manufacturing, aiming to extend its cash runway into at least Q4 2026.
Luvelta Out-Licensing: Sutro is actively seeking a partner to take over luvelta’s development, emphasizing that the decision to deprioritize was due to limited internal resources, not lack of faith in luvelta’s potential.
Clinical Pipeline: IND filing for STRO-004 is planned for the second half of 2025, with initial clinical data expected in 2026–2027. Additional INDs for STRO-006 and the dual-payload ADC are planned for 2026 and 2027.
Cost Savings: Management forecasts a dramatic decrease in expenditures starting in 2025 due to the winding down of luvelta and restructuring actions.
Partnerships: Ongoing discussions are targeting out-licensing of luvelta, with continued openness to additional collaborations and nondilutive funding for the pipeline.
